GlycoMimetics (GLYC) Earns Daily News Sentiment Rating of 0.15

Vanguard Group Inc. now owns 434,501 shares of the biotechnology company's stock valued at $2,359,000 after buying an additional 10,057 shares in the last quarter. 9 funds opened positions while 16 raised stakes. Tru Of Vermont, a Vermont-based fund reported 110 shares. Trading volume may be a very important factor for any investor. Deutsche Bancorp Ag owns 101,577 shares. Savings Bank Of Ny Mellon Corp reported 0% of its portfolio in GlycoMimetics Inc (NASDAQ:GLYC). Renaissance Technologies Ltd Company reported 117,900 shares.

Shares of NRG Energy Inc (NYSE:NRG) inclined 1.59% to $15.96. GlycoMimetics, Inc. (GLYC) is a part of Healthcare sector and belongs to Biotechnology industry. (NASDAQ:FBIO) shares moved to $4.23 after starting the day at $4.30. Jacobs Levy Equity Mgmt Inc owns 19,200 shares or 0% of their USA portfolio.

GlycoMimetics (NASDAQ:GLYC) traded up 1.81% during midday trading on Wednesday, reaching $13.49. Baker Bros Advsrs Lp holds 381,235 shares. Legal And General Group Incorporated Public Ltd Liability Corporation reported 1,315 shares. Zacks Investment Research lowered shares of GlycoMimetics from a buy rating to a hold rating in a research note on Thursday, May 11th. $30,050 worth of GlycoMimetics Inc (NASDAQ:GLYC) was bought by JUNIUS DANIEL M on Tuesday, December 20.

GlycoMimetics Inc (NASDAQ:GLYC) traded up 20.35% during midday trading on Tuesday, hitting $13.25. The 6 months bullish chart indicates low risk for the $403.88 million company. The average 1-year price target for Merck & Co., Inc. Canaccord Genuity set a $12.00 price target on GlycoMimetics and gave the stock a "buy" rating in a research report on Wednesday, March 1st. (NASDAQ:GLYC)'s stock about -9.36% from the 50-day high and 247.38% away from the 50-day low.

About 12.73 million shares traded or 300.31% up from the average. GlycoMimetics, Inc. (GLYC) earnings have risen with an annualized rate of 21.8% over the last 5 years. It has outperformed by 64.55% the S&P500.

The company's consensus rating is now Strong Buy, with 4 analysts rating it a Strong Buy, and 0 analysts rating it with a Hold. Therefore 100% are positive.

GLYC has been the subject of several other research reports.

More news for GlycoMimetics Inc (NASDAQ:GLYC) were recently published by:, which released: "Form 8-K GLYCOMIMETICS INC For: May 23" on May 24, 2017.

GlycoMimetics, a clinical-stage biotechnology company. Nea Management Company, Llc owns $109.53 million in GlycoMimetics, Inc., which represents roughly 48.29% of the company's market cap and approximately 43.29% of the institutional ownership. EyeGate Pharmaceuticals, Inc. (EYEG) revealed that it has received its first development milestone from a subsidiary of Valeant Pharmaceuticals International, Inc. under the Company's License Contract with Valeant, pursuant to which EyeGate has granted Valeant exclusive, worldwide commercial and manufacturing rights to the Company's EyeGate II Delivery System and EGP-437 combination product in post-operative ocular inflammation and pain in ocular surgery patients. It now has negative earnings. The Company operates through the identification and development of glycomimetic compounds segment.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

  • Joanne Flowers